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Editorial
About 10% of patients referred for hip fracture are in P2Y12 
receptor antagonists treatment (clopidogrel, prasugrel or ticagrelor) at 
the moment of trauma. Inhibitors of P2Y12 receptor are administered 
with aspirin as “dual antiplatelet therapy” after percutaneous coronary 
revascularization, in particular prasugrel and ticagrelor have only this 
indication. In a not negligible number of subjects however clopidogrel 
is used in primary or secondary prevention of cardiovascular events 
in alternative to aspirin. P2Y12 inhibition causes prolonged platelet 
inactivation. Full recovery of platelet function is expected only 7 days 
after the last dose of these drugs. Therefore patients treated with P2Y12 
receptor antagonists who need urgent/emergency non cardiac surgery 
have an increased risk of bleeding. In patients needing surgery within a 
few days, current ESC Guidelines recommend withholding clopidogrel 
and ticagrelor for five days and prasugrel for seven days prior to 
surgery [1]. Nevertheless the risk should be weighed against the risk of 
thrombosis in particular in patients underwent recent revascularization 
with medicated stents. For last generation medicated stents temporary 
suspension of dual antiplatelet agents may be considered 1 to 3 months 
after procedure. 
Patients with hip fracture represent a relevant problem both from 
an epidemiological and clinical point of view. Early surgery (within 24-
48 hours) is associated with a better outcome, both in terms of early 
(30 days) and long term mortality other than with improved functional 
recovery[2-3]. The British Orthopaedic Association recommends 
operation within 48 hours of admission for medically fit patients [4]. 
The risks associated with the operative management of patients on 
double antiplatelet agents include increased intra-operative bleeding 
and a higher risk of spinal haematoma where regional anaesthesia 
is used. Usually anesthesiologists and surgeons retain restoration 
of coagulative activity as a primary need. However, since results of 
hip fracture treatment are closely time-dependent, the mean time 
to surgery of 8 days reported after withdrawal of antiplatelet agents 
is unacceptable [5], being delayed surgery associated with higher 
complication rate and mortality. 
In the attempt to give a clinical guide in the last five years several 
papers examined the effects of P2Y12 inhibitors continuation in 
patients undergoing hip fracture surgery. These investigations however 
suffer from several limits: first no randomized studies have been 
published, second most studies involve a small number of patients 
therefore meta-analysis were needed, third no information about 
the indication for treatment are reported (is clearly different the risk 
in patients with recent revascularization in comparison to patients 
in primary or secondary prevention), fourth patients in antiplatelet 
agents have on average complex medical co-morbidities and an higher 
ASA risk, finally no information exist on prasugrel or ticagrelor. 
From available data two main questions should be answered: First 
is early hip fracture surgery for patients on clopidogrel (or prasugrel /
tigacrelor ) associated with worse postoperative outcomes compared 
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to patients not in P2Y12 inhibitors treatment? Second is early versus 
delayed surgery for these patients associated with worse postoperative 
outcomes? 
Leonidou et al. [5] reported an average time to surgery of 8 days 
in 27 patients in clopidogrel at admission in comparison to 2.3 days in 
378 control patients. Medical complications were more frequent and 
in hospital mortality higher in patients on clopidogrel at admission, 
although the difference was not statistically significant.
Feely [6] in a retrospective study identified 120 patients who were or 
not taking clopidogrel at the time of hip fracture. Mean time to surgery 
was less than 36 hours from admission in both groups. Perioperative 
bleeding complications and mortality were not significantly different 
between patients who were and were not taking clopidogrel at the time 
of hip fracture surgery. One-year mortality was 28% in the clopidogrel 
cohort and 29% in the control cohort (hazard ratio, 1.33; 95% CI, 0.84-
2.12; P=0.23). 
In a cohort study conducted in China 32 patients in clopidogrel were 
compared to 206 patients as control group [7]. Patients in clopidogrel 
treatment had a higher American Society of Anesthesiologists (ASA) 
grade and higher number of previous coronary stenting (P=0.002 and 
P<0.001, respectively). The rate of intraoperative blood transfusion, 
length of ICU stay, and overall hospital stay were higher in the 
clopidogrel group (all P<0.001). Postoperative complications were 
similar in the 2 groups. The 1-year mortality rate after surgery was 
significantly higher in the clopidogrel group compared with the control 
group (37.5% vs. 20.3%, P=0.030). Patients in clopidogrel treatment 
had a poorer prognosis after treatment of hip fracture in comparison 
to controls, however they had at admission an average higher ASA 
grade and more frequent previous arterial stenting therefore being a 
population at higher preoperative risk. 
In a retrospective study were included 39 patients with hip fracture 
treated with clopidogrel [8]. Total blood loss, amount of blood 
transfusion and rate of postoperative complications were compared 
between the period 2011 to 2013 in which patients underwent delayed 
surgery, five days or more after clopidogrel withdrawal, and the period 
from 2014 to 2016 in which patients underwent early surgery, within 48 
hours of admission. Although none of the end points differ between the 
two groups the author reported a different timing of bleeding. In the 
delayed surgery group it was noticed before surgery while it occurred 
Citation: Rostagno C (2018) Management of On-going Antiplatelet Treatment in Elderly Patients with Hip Fracture. J Perioper Med 1: e101. 
Page 2 of 2
Volume 1 • Issue 2 • 1000e101J Perioper Med, an open access journal 
in treatment with clopidogrel and the intervention may be performed 
general anesthesia (except if contraindicated) in the first 48 hours 
after trauma [12-14]. In patients in whom surgery must be postponed 
since they require medical stabilization the withdrawal of clopidogrel 
is questionable and justified only in order to perform neuraxial 
anesthesia. More information is needed for patients in dual antiplatelet 
treatment including prasugrel and tigacrelor.
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during the intra-operative phase in the early surgery group. Early 
surgery group had a significant lower length of hospital stay: 11 ± 3 vs. 
15 ± 4 days (p=0.004).
A systematic review identified after exclusion criteria 14 out of 
4321 studies about the effects of clopidogrel in surgery for hip fracture 
[9]. All 14 were case series with controls. Odds ratio for transfusion was 
1.24 (95% confidence interval 0.91 to 1.71), not statistically significant 
(p=0.14). The authors conclude that clopidogrel, if possible, should not 
be withheld throughout the perioperative period due to increased risk 
of cardiovascular events associated with stopping clopidogrel.Doleman 
et al. [10] compared results from patients undergoing early surgery on 
clopidogrel to a control group not taking clopidogrel. In patients in 
clopidogrel undergoing early surgery in hospital and 30-day mortality 
were not significantly increased (OR 1.10 95% CI: 0.48-2.54) although 
the need for blood transfusion significantly higher than in control 
group (OR 1.41 95% CI: 1.00-1.99).
Similarly in the meta analysis by Mattesi et al. [11], which 
included nine articles, early surgical management (<48 h) of patients 
receiving clopidogrel was demonstrated not to increase mortality 
at 30 days, 3 months or 1 year (between 25 and 30% mortality at 1 
year). Perioperative bleeding was not significantly increased in patients 
receiving clopidogrel. Morbidity and mortality are not increased in 
these patients if surgery is performed immediately or less than 48 h 
after admission.
On the basis of previously reported data and of our own experience 
on more than one hundred patients we will try to answer to the 2 
questions: 
Is early hip fracture surgery for patients on clopidogrel (or 
prasugrel/tigacrelor) associated with worse postoperative outcomes 
compared to patients not in P2Y12 inhibitors treatment? In hospital 
outcome in patients who need hip fracture surgery treated with 
clopidogrel (and in our experience, although limited to a dozen of 
patients, also in dual antiplatelet treatment with aspirin and prasugrel 
or tigacrelor) is not significantly different from controls. In particular 
none of the studies reported an increase in mortality and length of 
hospitalization. The risk of bleeding on average was higher in patients 
treated with P2Y12 inhibitors with sometimes the need for 1 more 
blood unit transfusion. It is not surprising that long term mortality is 
higher in patients in antiplatelet treatment since they more frequently 
suffer from severe cardiovascular diseases before trauma. Second is 
early versus delayed surgery for these patients associated with worse 
postoperative outcomes? Although the data are limited a delay in hip 
fracture surgery is associated with a worse postoperative outcome, to a 
higher rate of complications and finally to a longer hospital stay. 
In conclusion, in agreement with other authors, we believe that 
surgical delay in treatment of hip fracture is not justified in patients 
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